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ABSTRACT
HUMAN NIEMANN-PICK TYPE C2 DISEASE PROTEIN EXPRESSION,
PURIFICATION AND CRYSTALLIZATION
MAY 2011
YURIE T. KIM, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Scott Garman

Niemann-Pick type C2 (NPC2) protein is a soluble protein that binds unesterified
cholesterol. The protein helps transport unesterified cholesterol in tandem with the
membrane protein Niemann-Pick type C1 (NPC1). Defects in either of proteins can cause
Niemann-Pick type C disease (NPC), which results in the accumulation of unesterified
cholesterol and lipids in the late endosome and lysosome. NPC is an autosomal recessive
lysosomal storage disease affecting 0.35~2.20 per 100,000 people. Here we present the
structural analysis of the human NPC2 glycoprotein, including expression, purification,
functional analysis, homology modeling, and crystallographic studies. Human NPC2 was
expressed from baculovirus-infected Trichoplusia ni (Tn5) insect cells. The construct
contained a hexahistidine purification epitope tag, and the protein was purified using
Nickel affinity column chromatography. The purified protein was used in binding studies
with dehydroergosterol (DHE), showing that human NPC2 was functional. Using the
structure of bovine NPC2, we made a homology model and mapped the human mutations
onto the model. Some modeled proteins, such as the V30M and S67P variants, are
unclear as to how they lead to disease, thus a structure of the human protein would be
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informative. Crystallization screens of human NPC2 were performed and led to crystals
with a needle-like morphology, which diffracted to 4Å resolution. The structure of human
NPC2 will be useful for understanding the mechanism of cholesterol binding and
trafficking in cells, and to better understand the human metabolic disease NPC.
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CHAPTER 1
INTRODUCTION
Cholesterol is a very well known molecule with a wide range of cellular
functions. Cholesterol is essential for the synthesis of steroid hormones, vitamin D, bile
acids and the synthesis of cellular membranes. Due to the key role that cholesterol plays
in the health of cells a well-regulated and efficient means of transport is required for
cholesterol homeostasis [1].
There are four mechanisms that maintain cholesterol homeostasis. First, cells can
utilize enzymes to synthesize cholesterol. Secondly, cholesterol can be imported from
outside the cell by endocytosis. Thirdly, cholesterol can be extracted from lipid droplets.
Fourth, cholesterol can be removed from the cell membrane [2]. Two of the major
sources of cholesterol in the human body are cholesterol absorbed from dietary intake in
the intestine, and cholesterol synthesized in the liver. Even though every eukaryotic cell
can synthesize cholesterol the majority of cell utilize cholesterol derived from other
tissue, and it is important to see how cholesterol is delivered from one cell type to another
cell type [3].
In the human body, cholesterol from the liver and the intestine form low-density
lipoproteins (LDL), containing lipids, cholesterol, and protein. These lipoproteins are
circulated through the circulatory system [3]. Cells containing the low-density lipoprotein
(LDL) receptor recognize these lipoproteins [4]. After recognition of LDL by LDL
receptors, clathrin complexes assemble to make clathrin–coated pits, which result in
endocytosis [5]. The endocytosed vesicle is then fused to the early endosome [5]. In the
early endosome, due to the acidic pH of the organelle, the LDL-receptor/lipoprotein
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complex disassembles, and the LDL-receptor is transported back to the plasma membrane.
Throughout the transport of the LDL-particle, the cholesterol being transported is in the
esterified form (Figure 1). Esterified cholesterol has fatty acids attached to the
cholesterol-3-oxygen. Once the LDL-receptor/lipoprotein complex disassembles, acid
lipases hydrolyze the esterified cholesterol, replacing the fatty acid on the cholesterol-3oxygen with hydrogen, resulting in unesterified cholesterol (Figure 1). Unesterified
cholesterols then accumulate in the late endosome/lysosome [2]. As mentioned earlier,
cholesterols are needed for synthesis of steroid hormones, vitamin D, bile acids and
maintenance of cellular membranes, which require transport out of the late
endosome/lysosome to the cytosol, endoplasmic reticulum, and mitochondria [2].
However, unesterified cholesterol cannot be transported by diffusion or active transport
out of the endosome/lysosome, due to the fact that unesterified cholesterol is insoluble in
an aqueous environment and is toxic to cells [1]. Hence, there must be a mechanism for
removal of unesterified cholesterol from the late endosome/lysosome. Currently, the most
clearly defined mechanism for cholesterol transport in the late endosome/lysosome
involves the resident lysosomal proteins NPC1 and NPC2 (Figure 1). NPC1 and NPC2
are named after Niemann-Pick disease type C, a disease characterized by the
accumulation of unesterified cholesterol in the late endosome/lysosome. NPC1 is a transmembrane glycoprotein with 13 trans-membrane passes [6]. NPC1 has one luminal Nterminal domain, two large luminal loops, a smaller luminal loop, and several cytosolic
loops [6]. NPC2 is soluble glycoprotein also known as HE1 [7]. It is known that NPC1
and NPC2 work in tandem to transfer unesterified cholesterol out of the late
endosome/lysosome[8] (Figure 1). However, the mechanism of traffic outside of late
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endosome/lysosome is not well understood.

Cholesterol

Figure 1: Cholesterol traffic and Niemann-Pick disease. Esterified cholesterols are delivered
within low-density-lipoprotein (LDL) particles. When esterified cholesterols enter cell through LD
L-receptor mediated endocytosis, vesicles goes to early endosomE, and esterified cholesterols are
unesterified by acid lipase. Unesterified cholesterols accumulate in late endosome and lysosome.
NPC1 and NPC2 work in tandem to transfer unesterified cholesterols out of late endosome/
lysosome. If either of NPC1, NPC2 or both lose their function, unesterified cholesterols
accumulate inside of late endosome/lysome which seem to cause Niemann-Pick disease type C
[9].

Mutations resulting in functionally defective NPC1 and/or NPC2 lead to the
accumulation of unesterified cholesterol in the late endosomes/lysosomes (Figure 1). In
NPC1 or NPC2 mutants, low cholesterol level in the ER membrane, with a threshold of 5%
of overall ER lipids, leads to even more esterified cholesterols delivered to endosome
[10]. When cholesterol levels are below the 5% of the threshold in the ER membrane,
SREBP (Sterol regulatory element binding protein, a membrane protein) binds to SCAP
(SREBP cleavage activating protein, also a membrane protein). Then the coat protein
complex II (COPII) is recruited to make COPII-coated vesicles, which transport the
complex to the Golgi complex. SREBP is then cleaved twice, and the liberated Nterminal fragment of SREBP is trafficked to the nucleus to trigger the transcription of
3

genes encoding the LDL-receptor and HMG-CoA reductase, one of the enzymes
regulating cholesterol synthesis [1, 3, 10].
Accumulation of unesterified cholesterol results in Niemann-Pick type C disease
(NPC). Symptoms and lifespans of individuals afflicted with this disease differ from
patient to patient. With the exception of severe infantile onset patients, brain
abnormalities are the most prominent symptoms followed by liver, spleen and lung
abnormalities [9, 11-13]. NPC is an autosomal recessive lysosomal storage disease, a
family of diseases characterized by the accumulation of substrates or ligands in the
lysosome. Some of these diseases can be treated through enzyme/protein replacement
therapy. This form of therapy involves the administration of the deficient enzyme/protein
intravenously to a patient. The administered drug then traffics to the lysosome through
the mannose-6-phosphate receptor or other pathway, where it reduces the dangerously
high levels of the accumulated substrate/ligand. Interestingly, NPC patients have more
problems than just accumulation of unesterified cholesterol. Liver and spleen samples of
NPC patients often show accumulation of sphingomyelin, bis (monoacylglycero)
phosphate (LBPA), and glycolipids (essentially glucosylceramide, lactosylceramide, and
ganglioside GM3). In the brain, alterations of glycosphingolipids (glucosylceramide,
lactosylceramide, and gangliosides GM3 and GM2) become visible [12].
The structures of bovine NPC2 and its complex with a cholesterol analog have
been determined [14, 15]. Because human NPC2 and bovine NPC2 have 80% sequence
identity [14], a homology model of human NPC2 based on bovine NPC2 can have great
predictive power. The bovine NPC2 has a seven beta-sheet sandwich structure, and its
structure has revealed a pocket and two cavities that make a tunnel while it is bound to its
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substrate [14, 15]. Likewise, our homology model predicts human NPC2 to share this
seven beta-sheet sandwich structure. The bovine NPC2 complex with cholesterol-3-Osulfate confirmed the fact that the pocket and the cavities widen to accommodate the
substrate. Due to the hydrophobic ligand that NPC2 binds, the tunnel of bovine NPC2 is
lined with hydrophobic residues, especially valine residues [15]. A comparison of the
protein sequence of bovine and human NPC2 shows seven residues that are not
conservatively substituted, four residues that are semi-conservatively substituted, and
sixteen residues that are conservatively substituted (Figure 2). Non-conservatively
substituted, semi-conservatively substituted and conservatively substituted residues were
mapped on the bovine structure (Figure 4). The structure shows non-conservatively
substituted and semi-conservatively substituted residues that are mostly on the outside of
the protein, suggesting that the core of the protein is highly conserved.
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Figure 2: Bovine and human NPC2 sequence alignment. Bovine and human NPC2 protein
sequences are compared for their difference. The signal sequence is not shown. Different amino
acid residues are colored. Orange color means not conserved substitution; yellow color means
semi-conserved substitution; green means conserved substitution. Glycosylation state for each
sequence are indicated by * sign. Human NPC2 has two glycosylations where as bovine NPC2 has
one glycosylation.

There are three potential N-linked glycosylation sites in human and two in bovine NPC2.
A potential site at N19 (residue numbering starting from the mature human NPC2
sequence, not the beginning of signal sequence) in both human and bovine NPC2 do not
actually have carbohydrate added; it is speculated that the presence of a proline residue
following N19 prevents the addition of an N-linked glycan [16, 17] (Figure 2). Bovine
and human NPC2 have N-linked glycans at the N39 position (Figure 2), and these
glycans seem to be very important in delivering NPC2 to late endosome/lysosome; this
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glycan is most likely the site at which the mannose-6-phosphate is attached resulting in
trafficking to the lysosome [16-18]. Bovine NPC2 lacks the attachment of an N-linked
glycan at N116, whereas human NPC2 does have an N-linked glycan attached at this
position (Figure 2). It is not clear what function the N-linked glycan at residue N116
plays in human NPC2, but removal of this glycan does not affect its ability to transfer
cholesterol [16, 17].

Precursor hNPC2
Signal
Sequence

Glycosylation state
2 kDa

2 kDa

His6-Tag
0.8 kDa

2 kDa

Total MW:
21.4kDa

hNPC2 Sequence
14.6 kDa

Processed hNPC2
Glycosylation state
2 kDa

2 kDa

His6-Tag
0.8 kDa

Total MW:
19.4kDa

hNPC2 Sequence
14.6 kDa

Figure 3: Molecular weight prediction of NPC2 gene. NPC2 protein sequence itself (Blue
line) is 14.6kDa and the sequence has three possible glycosylation sites. However the first
glycosylation site is not used [16, 17]. So, glycans are put to two glycosylation sites (Marked
by curly cane). Also, the construct contain His6 tag. Overall molecular weight is 21.4kDa for
precursor human NPC2 or 19.4 kDa for processed human NPC2.
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Figure 4: Bovine NPC2 structure and difference to human NPC2. Comparison between
bovine and human NPC2, every difference in amino acid residues is colored on bovine
structure. PDB ID 2HKA. Orange color means not conserved substitution; yellow color means
semi-conserved substitution; green means conserved substitution. The molecule that is depicted
with sphere is cholesterol-3-O-sulfate.

In spite of high similarity between bovine and human NPC2, human NPC2
structure is worth solving for two reasons. The first reason is to see the effects of diseasecausing mutations on the structure. From NPC2 patients, a list of mutations is shown on
Table 1. Many of the mutations result no expression or incomplete expression of NPC2
protein. Also, there are six missense mutations (Figure 5). Out of the mutations, there are
two mutations, V30M and S67P that cannot be easily explained why they affect NPC2
function. Interestingly, residue 30 is not conserved between bovine and human NPC2. Yet,
mutation to methionine produces disease in patients. By having the human wild type
NPC2 structure and V30M and S67P mutant NPC2 structures, the effects from the
mutation might be explained.
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Table 1: Mutations identified for NPC2. The table lists genotypical and phenotypical
changes from mutations. DNA numbering in genotype starts from first nucleotide residue of
cDNA that does not include intron sequence. Protein numbering in phenotype starts from first
amino acid residue of NPC2 containing signal sequence. α) Splice site mutation results various
NPC2 mutant sequences. β) Heterozygous mutation that one of alleles was found and yet the
other is not found to be defined. γ) The literature does not define mutation specifically.
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a)

b)

Figure 5: Location of mutational effects on NPC2. From the table 1, substituting mutations
are highlighted by showing side chains and by labeling protein code and residue number.
The protein code before residue number is wild type amino acid residue, and the protein code
after residue number is substituting amino acid due to mutation.
A) Substituting mutation effected residues are highlighted on bovine NPC2 structure.
PIB ID 2HKA. “W30” is highlighted blue because the residue is different between bovine and
human, yet mutation of the residue in human cause NPC2 disease.
B) Substituting mutation effected residues are highlighted on homology model of human NPC2.
Based structural information from PIB ID 2HKA. On the human NPC2 model, “V30M” is
highlighted blue for its residue number is same as W30 in bovine NPC2.

A second reason is to understand how NPC2 bind and transfer cholesterol. As
mentioned earlier, the trafficking of unesterified cholesterol outside of the late
endosome/lysosome is not well understood. By understanding how NPC2 binds and
transfers cholesterol, trafficking of cholesterol can be better understood. Because many of
molecular and cellular experiments are done with human NPC2, the human NPC2 protein
is a good candidate for structural studies.
In order to express a recombinant protein, there are several organisms that may be
used: bacteria, yeast, insect cells, and mammalian cells. Each of these systems has their
advantages and disadvantages. For the expression of human NPC2 protein, we have
chosen the baculovirus expression system in insect cells for several reasons. Insect cells
are often used to express proteins that require post-translation modifications. In previous
10

studies we have used various expression systems for other lysosomal proteins such as αN-Acetylgalactosaminidase (α-NAGAL). Attempts were made to express NAGAL in an
Escherichia coli system as well as a Kluyveromyces lactis yeast system. We saw
solubility problems in E. coli expressed NAGAL and saw hyperglycosylation in K. lactis
expressed NAGAL [24]. However, when NAGAL was expressed using an insect cell
expression system, using Trichoplusia ni (Tn5) insect cells, these problems did not occur.
Also, from the α-NAGAL structure resulting from crystallization of protein purified from
insect cells, an additional advantage was observed. Additional crystal contacts were
observed resulting from the pauci-mannose carbohydrates used by Tn5 insect cells [24].
Due to the success we experienced using insect cells to express α-NAGAL, we reasoned
that insect cells were the ideal expression system for NPC2.
In order to solve the structure of human NPC2, we have chosen X-ray
crystallography. NPC2 protein was produced through a baculovirus express system. A
His6 tag on C-terminus of NPC2 was useful tool for purification. Then the protein was
tested for its proper folding and proper binding capability in a fluorescence-based binding
assay. After binding assay, NPC2 were screened in crystallization experiments. Crystals
from the screen were shot at a synchrotron X-ray source and showed diffraction to 4Å
resolution.
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CHAPTER 2
RESULTS AND DISCUSSION
In order to express recombinant NPC2 in insect cells we decided to use a
baculovirus expression system. We opted to use the Bac-n-blue system from Invitrogen.
In this system a gene of interest has to be incorporated into a donor plasmid, pFastbacDUAL (Figure 6). This can be done through LR recombinase reaction, which switches a
ccdB/chloramphenicol cassette from the pFastbac-DUAL-DEST vector with the
NPC2/Ampicillin cassette in an entry vector, pCR8. The resulting plasmid has NPC2
under the regulation of the polyhedrin promoter flanked by two Tn7 recombination sites.
The donor plasmid was then used to transform DH10BacTM E. coli cells (Figure 6). The
DH10BacTM cells contain an inactivated baculovirus genome as well as a helper plasmid
containing the Tn7 recombinase gene used to recombine portion of the donor plasmid
with the baculovirus genome, resulting in an activated baculovirus containing NPC2
under the regulation of the polyhedrin promoter.

Signal sequence +NPC2 DNA sequence
LR reaction
NPC2
NPC2

NPC2

Figure 6: Construct diagram. Legend on next page
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Figure 6: Construct diagram. human NPC2 that has natural signal sequence and has six
histidines as a tag is placed in pFastbac TM Dual plasmid, a donor plasmid, by LR reaction
kit from Invitrogen. The plasmid has polyhedrin promoter (PPh). The recombinant NPC2
gene was placed after polyhedrin promoter. Upon transformation of pFastbac TM Dual
plasmid containing recombinant NPC2 gene to DH10BacTM, polyhedrin promoteR and
recombinant NPC2 gene are transferred to bacmid plasmid. The bacmid plasmid is used
for co-transfection of insect cells. The figure is modified from a figure in Invitrogen
manual (Catalog number A10606).

Once the recombinant baculovirus was generated, transfection of Spodoptera
frugiperda (Sf9) insect cells was performed. The initial virus stock generated from this
transfection was of insufficient titer, concentration of virus, and volume for large-scale
expression. In order to generate a high titer and high volume baculovirus stock, a number
of rounds of virus amplification were performed in Sf9 cells (Figure 7). Each round of
amplification was performed using an approximate multiplicity of infection (MOI) of .1
plaque forming units / cell. A total of four rounds of amplification were performed with
an increase of volume of 5mL to 500mL occurring in the fourth round of amplification.
The titer of each round of amplification was estimated using cell diameter, and secreted
levels of NPC2 after infection of Tn5 cells as a metric. The Tn5 cell line, BTITn-5B1-4,
derived from Trichoplusia ni embryonic tissue was used for expression due to its ability
to express and secrete proteins at a higher level than SF9 cells. Secreted levels of NPC2
were measured using anti-6x-His western blots. Once a high titer and high volume virus
stock was created, Tn5 cells were infected in order to express secreted NPC2. Infections
were carried out with an approximate MOI of 3, and the infection was allowed to
progress for three days before harvesting the supernatant.
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Infection

P2
virus

Volume 2 ml

P3
virus

Sf9 insect
cells

Infection
P1
virus

Volume 2 ml

Volume 30 ml

Co-transfection
Infection

P4
Virus
Volume 1 L

Tn5 insect
cells

Baculovirus
infection

Expressed
protein

Figure 7: Insect cell culture and baculovirus expression. Before expression of protein by
viral infection, healthy wild type insect cells, Sf9 and Tn5, were maintained. With
maintained Sf9 cells, baculovirus is expressed and assembled inside of cells and lyse out of
cells. Volume of virus from co-transfection is about 2ml, and titer ranges from 1 x 106 to
1 x107 pfu (plaque-forming-unit)/ml. However, for large scale infection, you need more
volume and higher titer. Amplification of the virus using Sf9 cells bring volume and titer up
during infection. With enough viruses, wild type Tn5 cells are used to express protein.
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P3

P1

26
17

P4

26
17

Figure 8: Western blot of expressed NPC2. Virus generation zero, P1, is virus that
was produced from co-transfection of Sf9 cells. P3 and P4 is virus that was amplified by
infecting Sf9 cells for second times and third times. To test viral presEnce, each virus
generation were used to infect Tn5 cells to express NPC2. And supernatant from the
infections are used to run Anti-his western blot. Coomasie staining SDS-Gel was not
done at this stage because the level of protein expression was too low.

Large-scale infection of Tn5 cells was difficult due to contamination of the
cultures. Overall, almost 6 liters of infection supernatant were harvested. The harvested
infection supernatant was buffer exchanged with nickel column binding buffer (250mM
NaCl, 50mM phosphate pH 7.0, .01% azide), and concentrated to 400ml. The purification
was done using a 5 ml column of Nickel charged resin (Ni-NTA). NPC2 was eluted from
the column using a linear elution profile with nickel column elution buffer (250mM NaCl,
50mM phosphate pH 7.0, .01% azide, 400mM imidazole). NPC2 eluted after most of the
proteins in the supernatant (Figure 9a). Fractionation of the elution was done with a
fraction volume equal 5 ml. Exact fraction numbers where NPC2 eluted on that
purification were from 37 to 46 (Figure 9b). Those fractions were combined, buffer
15

exchanged to 20mM ammonium acetate, pH4.5, and concentrated.

a)
hNPC2 purification
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600
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b)

Load

FT

1

27

37

39

41

26

43

45

2

20

hNPC2
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Figure 9: Purification of NPC2. a) Purification Chromatogram. Using FPLC with 5ml
Ni2+ -NTA column, NPC2 was purified. Wash buffer was 250mM NaCl and 50mM
phosphate buffer, with an elution buffer has 400mM imidazole, 250mM NaCl, and 50mM
phosphate buffer. The gradient was from 100% wash buffer to 40% wash buffer and 60%
elution buffer. b) Fraction samples loaded Coomassie stained gel. Fractions from FPLC
purification were used to run SDS gel stained with coomassie-blue. Each fraction was 5ml
and fraction from 37 to 46 was combined after the gel.
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The purified NPC2 was then subjected to a cholesterol-binding assay. The
purpose of the binding study was to test the insect cell expressed human NPC2 for its
ability to bind cholesterol in order to prove that the protein was active. If the protein is
correctly folded then it should be able to bind fluorescent cholesterol, and show a change
in the fluorescence spectrum [14]. The binding assay was performed by incubating
dehydroergosterol (DHE) with NPC2, in binding buffer (20 mM citrate pH 5.5, 150 mM
NaCl). Upon binding of DHE to a cholesterol binding protein, such as NPC2, the DHE
fluoresces after excitation due to a conjugated triene system; however, the fluorescence is
quenched by an aqueous environment [25, 26]. Figure 14 (in the appendix) might seem to
contradict the previous statement, but there have been observations of dimerization of
DHE and of low quantum yield in chloroform [27, 28]. Comparing the spectrum from
Friedland, Natalia et al. [14] to our data (figure 10c) a similar trend in fluorescence is
observed. Also, the negative control of our NPC2 alone and DHE alone in binding buffer
shows minimal fluorescence. The reason why NPC2 alone has an increase in fluorescence
around 345nm is due to light scattering of NPC2 or other small particles. The
fluorescence data shows that human NPC2 expressed by insect cells is able to bind
unesterified cholesterol, and is therefore active.
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a)

b)

c)

12000

Fluorescence intensity

10000
8000
6000

NPC2
DHE

4000

NPC2+DHE

2000

0
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350

360
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380

390

400

410

420

430

440

450

Emission wavelength (nm)

Figure 10: Fluorescent assay. a) NPC2 and DHE complex fluorescent spectra of Natalia et
al. [14]. Buffer (20 mM citrate/150 mM NaCl, pH 5.0) was mixed with NPC2 alone (final
concentration 10 M), DHE alone (final concentration 1M), and human NPC2/ DHE (final
concentration NPC2: 10 M and DHE: 1 M). b) chemical structure of cholesterol and
dehydroergosterol (DHE) [29]. c) NPC2 and DHE complex fluorescent spectra. Buffer
(20 mM citrate/150 mM NaCl, pH 5.5) was mixed with human NPC2 alone (final
concentration 10 M), DHE alone (final concentration 1 M), and human NPC2/ DHE (final
concentration NPC2: 10 M and DHE: 1 M).

Once we confirmed that our purified NPC2 was biologically active we initiated
crystallization screening. When human NPC2 was screened with the Precipitant Synergy
screen (Emerald BioSystems), most of the crystallization conditions showed a sign of
precipitation shortly after the drop was set-up. However, one condition (46) showed small
crystals after three weeks at room temperature (Figure 11a, b). In a follow-up experiment,
the condition was diluted to 60% strength, and improved crystals were observed (Figure
11c). This result indicates that by lowering the concentration of one or more of the
18

components the rate of nucleation is slowed. By lowering the nucleation rate, fewer
nucleation events occur, which results in larger crystals.

A)

B)

C)

Figure 11: Crystalized human NPC2. NPC2 were crystallized in condition a-c)
16.75% (w/v) PEG 3350, 10.05% (v/v) isopropanol, 0.2M (NH4)3 Citrate/Citric acid
pH 4.5. a) was crystallized during screen and it was confirmed by crystallizing b) was
in same condition again. Was crystallized with same condition but diluted that conditi
on with 20mM ammonium acetate pH4.5 (precipitant: ammonium acetate = 6:4).

We then set out to determine if the crystals obtained through screening were in
fact protein crystals and not inorganic salt crystals. In order to determine if the crystals
we grew were salt or protein, we decided to look at the diffraction pattern of the crystal.
The diffraction data lets us determine whether the crystal is protein or salt. Salt only
diffracts to high resolution, but if the crystal contains macromolecules, such as protein,
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then low-resolution spots should be present. Depending on the crystal quality, highresolution diffraction patterns may or may not be visible for protein crystals. So, in order
to see whether the crystal is protein or salt, low-resolution diffraction patterns in
diffraction image will show the difference.

a)

b)

Figure 12: Diffraction images. a) A diffraction image that was from a crystal, shown in
figure 11a. The X-ray beam was from RU-H3R generator (Rigaku) b) A diffraction image
that was from a crystal shown in Figure 11c. The X-ray beam was from micro-beam of
Argonne Advanced photon source in Chigago, IL.

The initial crystals from the Precipitant Synergy screen (Emerald BioSystems)
condition 46 (figure 11a) were harvested and shot with the in house X-ray generator. An
image of diffraction data is shown on figure 12a. Even though there are mostly faint spots,
a few brighter spots are observed at low resolution. This data allowed us to confirm that
the crystals are in fact protein and diffracted to approximately 8Å . The optimized crystals
from the diluted condition 46 (Figure 11c) were exposed to shot at a much brighter X-ray
source, the Argonne Nation Laboratory synchrotron. The brighter synchrotron x-rays
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showed that the crystals diffracted to 4Å resolution (Figure 12 b).
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CHAPTER 3
FUTURE DIRECTIONS
The human NPC2 crystal should be optimized to make bigger crystals in order to
improve the diffraction images. Also, the V30M and S67P mutants (Figure 5) can be
expressed and crystallized. Comparison of the wild type human NPC2 to the mutant
NPC2 structures might reveal the molecular basis for disease in patients with those
mutations. In order to understand how NPC2 interacts with NPC1, NPC2 can be cocrystallized with N-terminal domain (NTD) of NPC1. The human NPC1 NTD (which
binds cholesterol) has been expressed in baculovirus-infected insect cells and crystallized
[30], so that both proteins are available for co-crystallization experiments. Moreover, cocrystallization experiments with and without cholesterol can reveal the mechanism of
binding and transfer of cholesterol between NPC1 and NPC2. The co-crystal structure
may show that the cholesterol binding pockets of each protein do not interact; even so,
this would be an interesting result. Mutagenesis of NPC1 NTD has identified the regions
on that protein responsible for the interaction with NPC2, so it may be possible to mutate
these residues to make a tighter interaction more suitable for crystallization experiments.
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Figure 13: Superimpose of sterol bound to NTD and NPC2 proteins. The cyan
molecules are NTD of NPC1 protein structure complex with cholesterol (PDB ID:
3GKI). The green molecules are NPC2 protein structure complex with Cholesterol-3-Osulfate (PDB ID: 2HKA). Those molecules are superimposed upon sterols that each of th
em bound.
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CHAPTER 4
METHODS
Plasmid construct/ NPC2 expression
The NPC2 gene (including the native signal sequence) was inserted by Nilima
Kolli into a bacmid via a LR reaction and transformed into Escherichia coli cells. The
construct included a C-terminal His6. The LR reaction uses site specific recombination
by utilizing bacteriophage lambda process. The gene, flanked by attL1 and attL2
sequences, cross with ccdB, flanked by attR1 and attR2 sequences. Removal of the
suppressor ccdB gene allows the E. coli to grow. In Gateway LR clonase II mix from
Invitrogen, integrase and excisionase enzymes conduct the reaction. The recombinant
bacmid was used to co-transfect Sf9 cells to produce virus that has NPC2 gene. Sf9 cell
line is derived from ovarian tissue of the fall armyworm, Spodoptera frugiperda. First
amplification o
2ml of 9 x 105 Sf9 cells/ml. Later amplifications were done by adding 16.7ml virus/1L
insect culture. For protein expression, Tn5 cells were infected with the viruses that were
produced by Sf9. Tn5 cell line, BTITn-5B1-4, is derived from originally the Trichoplusia
ni embryonic tissue. Volume of virus used was with same ratio as amplification of virus,
16.7ml virus per 1L insect culture. After an infection, expression level was confirmed by
western blot using either anti-NPC2 or anti-His6 as primary antibodies.
Purification
Prior to purification, the infection supernatant containing NPC2 was concentrated
and buffer exchanged nickel binding buffer (250 mM NaCl, 50mM sodium phosphate pH
7, and .01% azide). The His6-tag on the C-terminus of NPC2 was used for affinity
purification of the protein using nickel-nitrilo-triacetic acid resin (Ni2+-NTA) column
24

chromatography. Wash buffer was 250 mM Sodium chloride and 50mM phosphate buffer
pH 7. 100% elution buffer is 400mM imidazole, 250mM NaCl, and 50mM phosphate
buffer. A 5ml column was utilized. Elution fractions were collected in 5mL increments.
After purification, fractions 37 to fraction 46 were combined, and buffer was exchanged
with 20mM ammonium acetate, pH4.5. The buffer exchanged protein solution was

determined to be 16.8mg/ml by Abs280 measurements.
NPC2 protein binding assay
The protocol for the binding assay was adapted from Friedland, Natalia et al [14].
Intensity of fluorescence was measured using a Fluorolog 3-21 spectrometer equipped
with a 450W xenon arc lamp, a double excitation monochromator, a single emission
monochromator, and a cooled PMT [31]. The buffer was 20 mM citrate and 150 mM
NaCl, pH 5.5. DHE was dissolved in pure methanol (optima) and the concentration was

trol, buffer alone and NPC2 protein
alone with buffer and DHE alone with buffer were prepared. The samples were incubated
for at least an hour at 4℃ prior to the fluorescence measurement. The samples were then
transported to a quartz microcell. Then the fluorescence was measured using an excitation
wavelength 338 nm with band pass slit of 0.5 nm. Fluorescence emission was measured
from 340nm to 450nm with band pass slit of 0.5 nm.
Crystallization/ Optimization of NPC2 crystal
Using the Precipitant Synergy crystallization kit (Emerald BioSystems), 1μL of
purified human NPC2, at a concentration of 8 mg / mL, was mixed in a ratio of 1:1 with
the crystallization buffers contained in the kit, and then added to a sitting drop
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crystallization tray. The initial crystals formed in condition 46 (16.75% (w/v) PEG 3350,
10.05% (v/v) isopropanol, 0.2M (NH4)3 Citrate/Citric acid pH 4.5). To optimize the
crystals the initial condition was diluted with 20mM ammonium acetate pH4.5 to 60% of
the original concentration.
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APPENDIX
INSECT CELL CULTURE AND STERILE TECHNIQUE

In baculovirus expression, large scale expression depends on scaling wild type
insect cells up from small volumes. Usually small cultures such as adherent cultures of
5ml or 15ml or suspension cultures of 30ml are the start up volume. Depending on
temperature of culture room or depending on which shakers you are using, the cell
growth rate can be different, but usually cells go to confluence about three to four days.
So, large scale culture of 1L means approximately 2 weeks of preparation before. If you
get any contamination in the 1L culture, you might have to go back to small scale in
worst scenario. For the reason, set ups are usually done in duplicate and small scale
cultures are always maintained just in case. Back up cultures are there to save time if
contamination happens to affect actual experiment cultures. However, without sterile
technique, back up cultures are also most likely to be contaminated. The techniques are as
following: Before starting any culture, sterilize each flasks right before they will be used.
This reduces the likelihood that a possible contaminant will diffuse into the flask. Before
sterilization, the flask should be examined for damage to the flask or the cap filters. If the
flask itself is damaged, the flask is thrown away; if the cap’s filter is damaged, the top of
cap is covered with autoclave tape to plug any holes. After sterilization and while the
flask are cooling, culture hood’s UV is turned on for 15 minutes and hood is turned to
equilibrate air inside for 5 to 10 minutes to prevent any contaminant inside the hood
going into the cultures. When that preparation is all done, experiment actually starts. With
70% ethanol, wipe work area and put ethanol on hands and arms. During experiments,
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hands are avoided above the opened flask, and flasks are tilted to avoid too much air
blowing down culture, especially for flasks that have large brim. Careful technique still
does not avoid contamination entirely; there are other factors involved.

Interpretation of contamination data
Because of prolonged contamination, detailed data were collected in order to
detect patterns of contamination. The detailed data started from April 17th 2010 and
ended September 3rd 2010. During the time, there had been 218 experiments of different
cell type and volume. Overall, we saw 10 occurrences of contamination, leading to
overall contamination rate of about 4.6%. Even though the rate is very low, the rate is still
higher than expected. If volumes of 30mL and less are excluded, the rate increases to
10.5%. Moreover when volume of 30mls or less are excluded, the contamination rate of
Tn5 cells increases a little bit to 10.6%. All of the contamination was from bacteria. So,
assuming that bacterial growth rate is fast, expectation is 24 hours are more than enough
time for them to take over. And when bacteria take over, culture gets cloudy and smells
distinctively different. Among ten contaminations only two or possibly three were able to
take over the culture within a day without my intervention. Others took more than two
days to take over the culture without my opening the flask. That could mean many things
but if I have to pick reason why that might have happened, I can tell two things. A first
possibility is contaminant might have been introduced somehow while they were shaking.
A second possibility is those bacteria might take longer than typical to grow.
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Table A.1: Contamination results. From April 17th 2010 to September 3rd 2010, 218 set ups
regardless of cell type and volume of set up are done. Over all contamination that occurred
during that time is 10 occurrences. Cell type is cells that were used to set up. Volume of cultures
is volume of media plus cells for the set up. Contamination section indicate number of
contaminated flask out of set ups done on the date. Take over time is rough estimate of time
contaminant took to take over whole flask.

Dehydroergosterol
Dehydroergosterol (DHE) is a small molecule that is analog of cholesterol. As
mentioned previously, DHE fluoresces when it is surrounded in a hydrophobic
environment. In order to make sure of the fact, DHE had been added to pure methanol,
pure chloroform and 20 mM citrate/ 150 mM NaCl buffer. Figure 14 shows that pure
methanol have higher fluorescence than the buffer which is expected for the buffer is
aqueous environment. But in pure chloroform, DHE was expected to fluoresce for
chloroform is hydrophobic. However, literature reports show the dimerization of DHE
and of low quantum yield in chloroform [27, 28] suggest the quenching affect from
dimerization. So, considering only DHE in pure methanol, DHE does fluoresce in
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hydrophobic environment. With the result, if DHE fluoresce when DHE is combined with
NPC2, which means DHE is bound to NPC2 for the binding channel is hydrophobic.
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Figure A.1: Fluorescence of DHE in aqueous and hydrophobic medium. Fluorescence
spectra of DHE in various medium. Buffer (20 mM citrate/150 mM NaCl, pH 5.5), optima
pure methanol and optima pure chloroform were mixed with DHE alone which make DHE
concentration 1 M concentration.
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